Skip to main content

Werewolf Therapeutics, Inc. (HOWL)

NASDAQ: HOWL · IEX Real-Time Price · USD
16.19 0.19 (1.19%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap433.92M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out17.75M
EPS (ttm)-36.98
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume35,931
Open15.78
Previous Close16.00
Day's Range15.25 - 16.39
52-Week Range11.23 - 23.99
Betan/a
AnalystsStrong Buy
Price Target26.40 (+63.1%)
Est. Earnings DateNov 11, 2021

About HOWL

Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATORTM platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our molecules, which we refer to as INDUKINETM molecules, are intended to selectively target the tumor microenvironment, ...

IndustryBiotechnology
IPO DateApr 30, 2021
CEODaniel J. Hicklin, Ph.D.
Employees31
Stock ExchangeNASDAQ
Ticker SymbolHOWL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for HOWL stock is "Strong Buy." The 12-month stock price forecast is 26.40, which is an increase of 63.06% from the latest price.

Price Target
$26.40
(63.06% upside)
Analyst Consensus: Strong Buy

News

Werewolf Therapeutics to Present at H. C. Wainwright Global Investment Conference

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutic...

1 month ago - GlobeNewsWire

Werewolf Therapeutics Inks Solid Tumor Trial Collaboration With Merck

Werewolf Therapeutics Inc (NASDAQ: HOWL) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK) to evaluate WTX-124 in combination with Keytruda (pembrolizu...

Other symbols:MRK
2 months ago - Benzinga

Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program

Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, in combination with KEYTRUDA® (pembrolizumab) as a treatment for pati...

2 months ago - GlobeNewsWire

Werewolf Therapeutics Reports Second Quarter 2021 Financial Results and Business Update

CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of condit...

2 months ago - GlobeNewsWire

4 Global IPO Stocks Outperforming the S&P 500 Over the Past Month

In light of the global initial public offering market recording its strongest second quarter in two decades by volume and proceeds, four stocks that had their IPO during the past three months and outper...

Other symbols:RAIN
2 months ago - GuruFocus

Werewolf Therapeutics Announces Its Addition to the Russell 2000® Index

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...

3 months ago - GlobeNewsWire

Werewolf Therapeutics Reports First Quarter 2021 Financial Results

- Recently completed upsized initial public offering raising $120.0 million in gross proceeds - - Recently completed upsized initial public offering raising $120.0 million in gross proceeds -

4 months ago - GlobeNewsWire

Werewolf Therapeutics to Present at Jefferies Virtual Healthcare Conference 2021

CAMBRIDGE, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics ...

4 months ago - GlobeNewsWire

Werewolf Therapeutics IPO: HOWL Stock Comes Out Howling on First Day of Trading

Werewolf Therapeutics (HOWL) stock is doing incredibly well for its first day of trading on the Nasdaq following its IPO. The post Werewolf Therapeutics IPO: HOWL Stock Comes Out Howling on First Day of...

5 months ago - InvestorPlace

Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutic...

5 months ago - GlobeNewsWire

Werewolf Therapeutics looks to make a killing in the public markets with a $100M IPO

After banking $72 million at the start of the year, Werewolf Therapeutics now wants an IPO.

6 months ago - FierceBiotech

Werewolf Therapeutics IPO Registration Document (S-1)

Werewolf Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

6 months ago - SEC